7 research outputs found
Supporting files for article "Monovalent metal ion binding promotes the first transesterification reaction in the spliceosome"
No full text<p>Supporting files for the article "Monovalent metal ion binding promotes the first transesterification reaction in the spliceosome". The deposition contains:</p><p>1. Cp2k input files and basis sets for running unbiased and biased density functional theory (DFT) quantum mechanics (QM)/ molecular mechanics (MM) molecular dynamics (MD) simulations with cp2k for the spliceosome from Saccharomyces cerevisiae stalled in the C complex state.</p><p>2. Custom Python script that was used to extract relevant interatomic distances, number of metal-water contacts and analyze hydrogen bonding from collected molecular dynamics trajectories along with example files.</p><p>3. Initial structure of the spliceosome complex and final frames of performed MD simulations.</p>
The Proceedings of the South Carolina Historical Association
No full textAnnually, the association publishes a journal, The Proceedings, which consists of papers presented at the annual meeting.
Barbarians as a Destabilizing Factor in the Late Roman Empire: The Case of Magnus Maximus by Walter Roberts, Graduate Student – University of South Carolina (Columbia)
Anianus of Orléans and the Barbarians at the Gates by Tracy Keefer, Graduate Student – University of South Carolina (Columbia)
Physicians, Sorcerers, and Saints in Merovingian Gaul by Allen Jones, Graduate Student – University of South Carolina (Columbia)
The Planters of St. John’s Parish (Colleton): 1675-1790 by Laylon Wayne Jordan – University of Charleston
“Loyal Women of Palmetto”: Black Women’s Clubs in Charleston, South Carolina by Cherisse R. Jones, Graduate School – Ohio State University
South Carolina’s Board of Indian Commissioners and the Struggle to Control the Public Indian Trade by Michael Morris – University of South Carolina (Aiken)
“Radical Journalists, Generalist Intellectuals and Good Neighbors: Alternative Intellectuals and United States-Latin American Relations” by Virginia S. Williams – Winthrop University
Why Didn’t We See It Coming? Predicting the Soviet Future: An Exercise in Futility by Valdis Lumans – University of South Carolina (Aiken)
From the Gay 90’s to the Roaring 20’s: The Role of Clothing in the Lives of South Carolina Women, 1890-1925 by Molley E. Hennen – University of South Carolina (Columbia)
Landscapes of Reform: The Material Culture of the New Deal in Manchester, South Carolina, 1934-1945 by Albert C. Hester – University of South Carolina (Aiken)
The Charleston Orphan House: The First One Hundred Years by Susan L. King – Archives of the Diocese of Charleston
Francis Lieber at South Carolina College, 1835-1856 A Clash of Values by Gerald R. Roys – Benedict College
The History of the Film Industry in South Carolina: The Early Years: 1902-1926 by Whitney Miller – Michigan State University Archives & Historical Collections
“Gone Out South”: A Nineteenth-Century Social and Economic Interchange between the Citizens of Maine and South Carolina Port Towns by Constance Fournier
Charleston’s French Revolutionary Consul: Michel-Ange—Bernard de Mangourit, 1792-1794 by Robert Alderson – University of South Carolina (Columbia
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
No full textPembrolizumab, as monotherapy in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with a combined positive score (CPS) ≥1 and in combination with platinum and 5-fluorouracil (5-FU) in the overall R/M HNSCC population, received US FDA approval based on the KEYNOTE-048 trial. Using public drug prices, from a US payer perspective, we evaluated the cost-effectiveness of each pembrolizumab regimen vs. cetuximab + platinum+5-FU (EXTREME regimen, trial comparator), cisplatin + docetaxel + cetuximab (TPEx regimen), cisplatin + paclitaxel, and platinum+5-FU. A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting. Progression-free and overall survival were modeled using long-term extrapolation of KEYNOTE-048 data and, for alternative comparators, data from a network meta-analysis was used. Time-on-treatment was derived from KEYNOTE-048 or approximated using network meta-analysis progression-free survival estimates. Costs included first-line and subsequent treatments, disease management, adverse events, and terminal care costs. Utilities were derived from the KEYNOTE-048 Euro-QoL five-dimension data and using a US algorithm. In the CPS ≥1 R/M HNSCC population, pembrolizumab monotherapy was dominant vs. EXTREME and TPEx regimens, and cost-effective (at 86,827/QALY) and cisplatin + paclitaxel (1769/QALY), platinum+5-FU (89,505/QALY). Sensitivity analyses showed a high cost-effectiveness probability for pembrolizumab at the $100,000/QALY threshold. First-line pembrolizumab monotherapy in patients with CPS ≥1, and pembrolizumab combination therapy in the overall R/M HNSCC population is cost-effective from the perspective of the US payers.</p
Frontiers in Monetary Theory and Policy: Summary of the 2008 International Conference Organized by the Institute for Monetary and Economic Studies of the Bank of Japan
No full textClinical and Economic Impact of Recurrence in Early-Stage Non-Small Cell Lung Cancer Following Complete Resection - supplementary material
No full textsupplementary figures 1-3 </p
DataSheet_1_Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.docx
No full textBackgroundOverall survival (OS) is the most patient-relevant outcome in oncology; however, in early cancers, large sample sizes and extended follow-up durations are needed to detect statistically significant differences in OS between interventions. Use of early time-to-event outcomes as surrogates for OS can help facilitate faster approval of cancer therapies. In locally advanced head and neck squamous cell carcinoma (LA-HNSCC), event-free survival (EFS) was previously evaluated as a surrogate outcome (Michiels 2009) and demonstrated a strong correlation with OS. The current study aimed to further assess the correlation between EFS and OS in LA-HNSCC using an updated systematic literature review (SLR) focusing on patients receiving definitive chemoradiation therapy (CRT).MethodsAn SLR was conducted on May 27, 2021 to identify randomized controlled trials assessing radiotherapy alone or CRT in the target population. Studies assessing CRT and reporting hazard ratios (HRs) or Kaplan-Meier data for OS and EFS were eligible for the analysis. CRT included any systemic treatments administered concurrently or sequentially with radiation therapy. Trial-level EFS/OS correlations were assessed using regression models, and the relationship strength was measured with Pearson correlation coefficient (R). Correlations were assessed across all CRT trials and in trial subsets assessing concurrent CRT, sequential CRT, RT+cisplatin, targeted therapies and intensity-modulated RT. Subgroup analysis was conducted among trials with similar EFS definitions (i.e. EFS including disease progression and/or death as events) and longer length of follow-up (i.e.≥ 5 years).ResultsThe SLR identified 149 trials of which 31 were included in the analysis. A strong correlation between EFS and OS was observed in the overall analysis of all CRT trials (R=0.85, 95% confidence interval: 0.72-0.93). Similar results were obtained in the sensitivity analyses of trials assessing concurrent CRT (R=0.88), sequential CRT (R=0.83), RT+cisplatin (R=0.82), targeted therapies (R=0.83) and intensity-modulated RT (R=0.86), as well as in trials with similar EFS definitions (R=0.87), with longer follow-up (R=0.81).ConclusionEFS was strongly correlated with OS in this trial-level analysis. Future research using individual patient-level data can further investigate if EFS could be considered a suitable early clinical endpoint for evaluation of CRT regimens in LA-HNSCC patients receiving definitive CRT.</p
Table_1_Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors.docx
No full textBackgroundFront-line therapy with an EGFR tyrosine kinase inhibitor (TKI) is the standard of care for treating patients with advanced nonsquamous NSCLC with the common sensitizing EGFR exon 19 deletion and exon 21 L858R point mutations. However, EGFR TKI resistance inevitably develops. The optimal subsequent therapy remains to be identified, although platinum-containing chemotherapy regimens are often administered. Our objectives were to describe baseline characteristics, survival, and subsequent treatment patterns for patients with advanced nonsquamous NSCLC with EGFR exon 19 deletion or L858R mutation who received a platinum-based combination regimen after front-line EGFR TKI therapy.MethodsThis retrospective study used a nationwide electronic health record-derived deidentified database to select adult patients with advanced nonsquamous NSCLC, evidence of EGFR exon 19 deletion or L858R mutation, and ECOG performance status of 0-2 who initiated platinum-containing chemotherapy, with or without concomitant immunotherapy, from 1-January-2011 to 30-June-2020 following receipt of any EGFR TKI as first-line therapy or, alternatively, a first- or second-generation EGFR TKI (erlotinib, afatinib, gefitinib, dacomitinib) as first-line therapy followed by the third-generation EGFR TKI osimertinib as second-line therapy. Data cut-off was 30-June-2022. The Kaplan-Meier method was used to estimate overall survival (OS) after initiation of pemetrexed-platinum (n=119) or any platinum-based combination regimen (platinum cohort; n=311).ResultsThe two cohorts included two-thirds women (65%-66%) and 57%-58% nonsmokers; median ages were 66 and 65 years in pemetrexed-platinum and platinum cohorts, respectively. Median OS was 10.3 months (95% CI, 8.1-13.9) from pemetrexed-platinum initiation and 12.4 months (95% CI, 10.2-15.2) from platinum initiation; 12-month survival rates were 48% and 51%, respectively; 260 patients (84%) had died by the end of the study.ConclusionThe suboptimal survival outcomes recorded in this study demonstrate the unmet need to identify more effective subsequent treatment regimens for patients with EGFR-mutated advanced nonsquamous NSCLC after EGFR TKI resistance develops.</p
